ArticleCureus2026
Assessment of Neurodevelopmental Outcomes Using the Developmental Assessment Scale for Indian Infants and Growth Patterns Among High-Risk Infants From a Special Newborn Care Unit in Northern India: A Longitudinal Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess neurodevelopmental outcomes and growth in high-risk infants post discharge from a level 3 newborn unit. METHODOLOGY: Eligible high-risk infants were enrolled in this longitudinal follow-up study, and anthropometric measurements were interpreted using the WHO Anthro software (WHO, Geneva, Switzerland) at three, six, nine, and 12 months corrected age (CA). Neurodevelopment assessment was done using the Developmental Assessment Scale for Indian Infants (DASII) at six- and 12-month CA. Logistic regression analysis was used to identify risk factors associated with developmental delays.
resultAmong 296 high-risk infants, 194 completed 12-month follow-up; seven died (2.4%), and 95 were lost to follow-up. Motor delay affected 29 (12.6%) at six months and 15 (7.7%) at 12 months; corresponding figures for mental delay were nine (4%) and seven (3.6%). At 12 months, the strongest predictors of motor delay were shock (OR: 78.1; 95% CI: 26.6, 228), hypoxic-ischemic encephalopathy (HIE) (OR: 65.5; 95% CI: 14.1, 304), and meningitis (OR: 25.9; 95% CI: 8.2, 82.1). Significant predictors for mental delay included HIE (OR: 92.6; 95% CI: 12, 113.6), shock (OR: 79.6; 95% CI: 23.3, 271.7), meningitis (OR: 42; 95% CI: 9.3, 188), and ventilator support >24 hours (OR: 13; 95% CI: 6.4, 26.6). Other factors like birth weight <1000 grams (OR: 5.7; 95% CI: 2.0, 15.9) and sepsis (OR: 2.6; 95% CI: 1.4, 4.9) also remain significant risks throughout the first year. Growth faltering was greatest for weight/length-for-age Z-scores at three months and head circumference at nine months.
conclusionNeurodevelopmental delays declined by 12 months but persisted in a vulnerable subset, with shock, HIE, and meningitis emerging as the strongest predictors. Growth faltering was most evident in early weight/length indices and later in head circumference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.